This is a summary of the European public assessment report (EPAR) for Ninlaro. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Ninlaro. For practical information about using Ninlaro, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Ninlaro in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Therapeutic Area (MeSH)
ATC Code
L01XG03
ATC Item
ixazomib
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| ixazomib citrate | N/A | 伊沙佐米 |
EMA Name
Ninlaro
Medicine Name
Ninlaro
Aliases
N/ANo risk management plan link.
